FDA approves new breast cancer drug

By
March 14, 2007 18:15

The Israel Cancer Association (ICA) welcomed the US Food and Drug Administration announcement Wednesday that it had granted approval for the marketing of Tykerb, a drug for women with metastatic breast cancer that no longer responds to Herceptin. The FDA examined studies showing that when Tykerb (of GlaxoSmithKline) is given along with the drug Xeloda, another breast cancer drug from Roche Pharmaceuticals, the disease is kept under control better than with Xeloda alone. Tykerb is not in Israel's basket of health services, but it will probably be proposed for inclusion next year. The ICA said Tykerb, which prevents further decline of cancer in women with metastases, is yet another tool to fight common malignancies and to raise the recovery rate.


Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia

By UNIVERSITY OF MICHIGAN HEALTH SYSTEM

Israel Weather
  • 15 - 23
    Beer Sheva
    17 - 21
    Tel Aviv - Yafo
  • 12 - 18
    Jerusalem
    15 - 21
    Haifa
  • 19 - 27
    Elat
    16 - 27
    Tiberias